Med. praxi. 2019;16(3):143-147 | DOI: 10.36290/med.2019.021

DMARDs-treated patient in the care of a General Practitioner

MUDr. Martina Skácelová, Ph.D., prof. MUDr. Pavel Horák, CSc., MUDr. Eva Lokočová
III. interní klinika – nefrologická, revmatologická a endokrinologická, FN a LF UP Olomouc

Long-term therapy of rheumatic diseases, such as rheumatoid arthritis, spondyloarthritis or systemic connective tissue diseases,
using disease modifying drugs (DMARDs) can be connected with multiple complications. The most common are gastrointestinal
complications, there is also increased risk of infectious complications, hepatotoxicity and myelotoxicity. In this review the most
common complications, their management and recommendations for perioperative care and vaccination are described.

Keywords: disease modifying drugs, methotrexate, sulfasalazine, leflunomide, biologic therapy

Published: June 28, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová M, Horák P, Lokočová E. DMARDs-treated patient in the care of a General Practitioner. Med. praxi. 2019;16(3):143-147. doi: 10.36290/med.2019.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Šedová L, Štolfa J, Horák P, Pavelka K. Doporučení České revmatologické společnosti pro monitorování bezpečnosti léčby revmatoidni artritidy. Čes Revmatol 2009; 1(17): 4-15.
    2. Vencovský J, et al. Bezpečnost biologické léčby - doporučení České revmatologické společnosti. Čes. Revmatol. 2009; 3(17): 146-160.
    3. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014; 73(1): 3-5. Go to original source... Go to PubMed...
    4. Smolen J, Landewé R, Bijslma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6): 960-977. Go to original source... Go to PubMed...
    5. Šenolt L, Mann H, Závada J, Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro farmakologickou léčbu revmatoidní artritidy 2017. Čes. Revmatol 2017; 1(25): 8-16, 18-24.
    6. Rigby WFC, Lampl K, Low JM, Furst DE. Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. International Journal of Rheumatology. 2017; 2017: 9614241. Go to original source... Go to PubMed...
    7. Pincus T. Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol. 1998; 16(6): 667-668. Go to PubMed...
    8. Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology: Research and Reviews. 2017; 9: 67-79. Go to original source... Go to PubMed...
    9. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009; 68(7): 1100-1104. Go to original source... Go to PubMed...
    10. Rosandich PA, Kelley JT 3rd, Conn DL. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004; 16: 192-198. Go to original source... Go to PubMed...
    11. MacKenzie CR. Perioperative Medication Management in the Rheumatic Diseases. Current Reviews in Musculoskeletal Medicine. 2017; 10(3): 404-406. Go to original source... Go to PubMed...
    12. Horák P, Tegzová D, Závada J, et al. Doporučení ČRS pro léčbu nemocných se SLE. Čes. Revmatol. 2013; 21: 110-122.
    13. Kuchynka P, et al. Oční lékařství (2., přepracované a doplněné vydání). Grada 2016.
    14. Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford). 2009; 48(9): 1065-1068. Go to original source... Go to PubMed...
    15. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-422. Go to original source... Go to PubMed...
    16. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014; 73: 62-68. Go to original source... Go to PubMed...
    17. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis Ann Rheum Dis. 2010; 69: 325-331. Go to original source... Go to PubMed...
    18. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports project. Blood 2009; 113(20): 4834-4840. Go to original source... Go to PubMed...
    19. Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol. 2018; 70(9): 1399-1407. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.